0000950123-11-027977.txt : 20110323 0000950123-11-027977.hdr.sgml : 20110323 20110323092048 ACCESSION NUMBER: 0000950123-11-027977 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20110323 DATE AS OF CHANGE: 20110323 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CorMedix Inc. CENTRAL INDEX KEY: 0001410098 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-85411 FILM NUMBER: 11705268 BUSINESS ADDRESS: STREET 1: 745 ROUTE 202-206 STREET 2: SUITE 303 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908-517-9500 MAIL ADDRESS: STREET 1: 745 ROUTE 202-206 STREET 2: SUITE 303 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: PHARMABIO DEVELOPMENT INC CENTRAL INDEX KEY: 0001284041 IRS NUMBER: 562019326 STATE OF INCORPORATION: NC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: QUINTELES TRANSNATIONAL CORP STREET 2: 4709 CREEKSTONE DRIVE STE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 9199982000 MAIL ADDRESS: STREET 1: QUINTELES TRANSNATIONAL CORP STREET 2: 4709 CREEKSTONE DRIVE STE 200 CITY: DURHAM STATE: NC ZIP: 27703 SC 13G 1 g26581sc13g.htm SC 13G sc13g

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

CORMEDIX INC.
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
21900C100
(CUSIP Number)
December 31, 2010
(Date of Event Which Requires Filing of this Statement)
David B. Clement, Esq.
Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.
2500 Wachovia Capitol Center
150 Fayetteville Street
Raleigh, North Carolina 27601
(919) 821-1220
(Name, Address and Telephone Number
of Person Authorized to Receive Notices and Communications)

     Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

               o Rule 13d-1(b)

               o Rule 13d-1(c)

               þ Rule 13d-1(d)

*   The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following page(s))

 
 

 

                         
CUSIP No.
  
21900C100 
 Schedule 13G Page  
2 
   of   
3 
   Pages

 

           
1   NAME OF REPORTING PERSON

PharmaBio Development Inc.
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o
  (b)   o
     
3   SEC USE ONLY
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  North Carolina
       
  5   SOLE VOTING POWER
     
NUMBER OF   1,184,344 (1)
       
SHARES 6   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   -0-
       
EACH 7   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   1,184,344 (1)
       
WITH 8   SHARED DISPOSITIVE POWER
     
    -0-
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  1,184,344 (1)
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
   
  10.0% (2)
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  CO
1    Includes 789,563 shares of common stock (the “Common Stock”) of CorMedix Inc. (the “Issuer”) beneficially owned by PharmaBio Development Inc. (“PharmaBio”) and warrants beneficially owned by PharmaBio that are exercisable for 394,781 shares of Common Stock. Therefore, the total shares of Common Stock of the Issuer beneficially owned by PharmaBio is 1,184,344.
2    Calculated based on 11,408,274 shares of outstanding Common Stock of the Issuer on March 10, 2011, as reported in the Issuer’s Annual Report on Form 10-K for the period ending December 31, 2010 and filed with the Securities and Exchange Commission on March 11, 2011.

 

                         
CUSIP No.
  
21900C100 
 Schedule 13G Page  
3 
   of   
3 
   Pages
Item 1    
 
  (a) Name of Issuer
 
    CorMedix Inc. (the “Issuer”)
 
  (b) Address of Issuer’s Principal Executive Offices
 
  745 Rt. 202-206
Suite 303
Bridgewater, New Jersey 08807
 
Item 2    
 
  (a) Name of Person Filing
 
    PharmaBio Development Inc.
 
  (b) Address of Principal Business Office or, if none, Residence
 
  4208 Six Forks Road
Suite 920
Raleigh, NC 27609
 
  (c) Citizenship
 
    PharmaBio Development Inc. is a North Carolina corporation.
 
  (d) Title of Class of Securities
 
    Common stock, par value $0.001 per share (“Common Stock”).
 
  (e) CUSIP Number
 
    21900C100
 
Item 3    
 
    Not Applicable
 
Item 4   Ownership
 
  (a) Amount Beneficially Owned
 
    Includes 789,563 shares of common stock of the Issuer beneficially owned by PharmaBio and warrants beneficially owned by PharmaBio that are exercisable 394,781 shares of Common Stock. Therefore, the total shares of common stock of the Issuer beneficially owned by PharmaBio is 1,184,344.
 
  (b) Percent of Class:
 
    For PharmaBio, such 1,184,344 shares are 10.0% of the Issuer’s common stock based on the 11,408,174 shares of outstanding Common Stock of the Issuer on March 10, 2011, as reported in the

 

 

                         
CUSIP No.
  
21900C100 
 Schedule 13G Page  
4 
   of   
3 
   Pages
    Issuer’s Annual Report on Form 10-K for the period ending December 31, 2010 and filed with the Securities and Exchange Commission on March 11, 2011.
 
  (c) Number of Shares as to which such Person has:
 
    PharmaBio:
  (i)   sole power to vote or to direct the vote: 1,184,344
 
  (ii)   shared power to vote or to direct the vote: 0
 
  (iii)   sole power to dispose or to direct the disposition of: 1,184,344
 
  (iv)   shared power to dispose or to direct the disposition of: 0
Item 5   Ownership of Five Percent or Less of a Class
 
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
 
Item 6   Ownership of More than Five Percent on Behalf of Another Person
 
    Not Applicable
 
Item 7   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
 
    Not Applicable
 
Item 8   Identification and Classification of Members of the Group
 
    Not Applicable
 
Item 9   Notice of Dissolution of Group
 
    Not Applicable
 
Item 10   Certification
 
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

                         
CUSIP No.
  
21900C100 
 Schedule 13G Page  
5 
   of   
3 
   Pages
SIGNATURE
     After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: March 23, 2011
         
  PHARMABIO DEVELOPMENT INC.
 		  
  By:   /s/ Michael P. Troullis    
    Name:   Michael P. Troullis   
    Title:   President